Sanofi introduces new 340B payment model — report
Sanofi is proposing a new model for distributing drug discounts under the federal 340B program, according to the Wall Street Journal, in an effort that is almost certain to create pushback ...
View ArticleFDA approves BridgeBio's heart disease drug, setting up competition with...
The FDA approved BridgeBio’s acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label will give it a near-immediate boost against...
View ArticleTrump picks Johns Hopkins researcher Marty Makary to lead the FDA
President-elect Donald Trump selected Marty Makary to lead the FDA, choosing a Johns Hopkins University surgeon who has called the US government the “greatest perpetrator of misinformation during the...
View ArticleTrump picks former congressman and vaccine injury advocate to lead CDC
Physician, veteran and former Florida Congressman Dave Weldon is President-elect Donald Trump’s pick to lead the CDC, giving Robert F. Kennedy Jr. a key ally in his planned review of the safety of...
View ArticleTrump announces picks for FDA, CDC; Novartis seeks bolt-on deals, raises...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleGilead buys experimental HIV vaccines from a small Barcelona biotech
Long known for its HIV drugs, Gilead is further delving into the field by acquiring investigational vaccines for the stubborn virus from a little-known biotech in Spain. Gilead is paying an undisclosed...
View ArticleReplimune aims to raise $125M; Otsuka makes another deal with Ionis
Plus, news about Kanglin Biotechnology, Seelos, Orbus and Sonata: Replimune’s $125M offering: The biotech announced the offering four days after it submitted an FDA application for RP1 ...
View ArticleBiohaven's myostatin inhibitor misses primary endpoint in spinal muscular...
Biohaven’s stock fell in premarket trading on Monday after it announced a Phase 3 trial failure of its myostatin inhibitor in spinal muscular atrophy and obesity. The RESILIENT study did not ...
View ArticleCassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial
Is this the end for Cassava Sciences? After a problematic development path riddled with allegations of misleading investors, the biotech’s Alzheimer’s drug flopped on all endpoints in a Phase 3 study....
View Article#ASH24: Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as...
Incyte’s monoclonal antibody Monjuvi reduced certain follicular lymphoma patients’ risk of progression, relapse or death by 57% compared to placebo, the company announced Monday. The Phase 3 data,...
View ArticleMerck halts Phase 3 trial with PAH drug Winrevair following positive interim...
Merck is stopping a Phase 3 trial of its pulmonary arterial hypertension treatment Winrevair almost a year early following positive interim data, the company announced Monday. The trial, which was...
View ArticleMinnesota 340B revenue driven by hospitals and high-priced drugs, first state...
As the federal drug discount program known as 340B has seen rapid growth in recent years, Minnesota's Department of Health is looking to shine a light on where that growth is occurring. The first year ...
View ArticleTrump team asked Covid vaccine leader about heading NIH
The transition team for President-elect Donald Trump was still searching for its next National Institutes of Health director as recently as last week, multiple sources told Endpoints News, potentially...
View ArticleBristol Myers reveals more job cuts in New Jersey
Bristol Myers Squibb's cost-cutting initiative will lead to additional layoffs in Lawrenceville, NJ, the company revealed this month in a state WARN notice. A total of 197 cuts, some of which ...
View ArticleHow did Trump’s FDA pick land? Biotech stocks are up, and executives are...
Now that President-elect Donald Trump has made his choice for FDA commissioner, reactions and analysis are pouring in from biopharma executives and former staffers who know the agency’s inner workings....
View ArticleAlector says Alzheimer's program targeting microglia fails Phase 2, stock dives
Alector reported a Phase 2 failure for an AbbVie-partnered Alzheimer’s program Monday afternoon and said it will need to lay off staff. Researchers were examining whether the drug, known as AL002,...
View ArticleWhy Morgan Health is backing autism care provider Cortica
JP Morgan’s Morgan Health is rounding out its first three years of investing with its seventh investment. The health venture, which the bank launched to get a handle on healthcare costs for ...
View ArticleCradle Bio raises $73M Series B for protein-making AI software
European startup Cradle Bio raised a $73 million Series B round, fueling its plans to sell its AI-based protein-making software to more drugmakers. Cradle was founded in December 2021 by a team ...
View ArticleRoche’s TIGIT drug misses overall survival endpoint in Phase 3 lung cancer trial
Roche’s TIGIT drug has failed to clear the final hurdle in a late-stage cancer trial in what’s proving to be a mostly disappointing year for a drug class that was once seen as the next ...
View ArticleUpdated: Roche buys out CAR-T partner Poseida for $1B upfront
Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning. The Basel-based pharma giant will pay $9 per share in upfront cash, giving...
View Article